Could déjà vu and the 'Mandela effect' prove that alternate dimensions exist?

Are déjà vu and the Mandela Effect related? A theory by physicist Michio Kaku may help explain.

Nelson Mandela in 2011. Credit: Associated Press. Photo by Adrian Steirn.
Nelson Mandela in 2011. Credit: Associated Press. Photo by Adrian Steirn.

There may be a connection between two weird phenomena that science doesn't yet know how to fully explain. What if a sense of déjà vu, which is reportedly experienced by 60-70% of all people, is actually connected to something larger, a fascinating internet happening called the Mandela Effect?


We generally know what déjà vu feels like. When it comes, you get a feeling of familiarity, like you've experienced what is happening at some point before. While there is a pathological kind of déjà vu that is associated with epilepsy, scientists say that for healthy people the sensation is an anomaly of an individual memory. Individuals holding non-scientific beliefs often claim that déjà vu is an after-effect of reincarnation (and evidence for reincarnation). That déjà vu may be a mistake of your mind is supported by the fact that, while that moment of sudden recollection may be strong, the details of what we are actually remembering are either nonexistent or very hazy.

The Mandela Effect is an internet-related psychological phenomenon that proposes a reason why some people remember the same event public event one way and other people may have a completely different view of how it happened. It says, 'hold on, there can be another explanation here, outside of your possibly malfunctioning brain.' Of course, this explanation is also something science either rejects, or at least struggles to fully conceptualize.

In particular, the death of Nelson Mandela in 2013 spurred a strange feeling among many people (who connected on the Internet) that the famous anti-apartheid fighter actually died much earlier, in the 1980s, when he was still in prison. Similar stories have perpetrated in relation to pop culture knowledge, like the spelling of the children’s book series “The Berenstain Bears” - there are apparently quite a lot of people out there who can swear they remember the title as “The Bernstein Bears”. 


South African President Nelson Mandela smiles 16 July 1966 in Paris as he answers journalists' questions during his official visit to France. (Photo credit should read PIERRE VERDY/AFP/Getty Images)

What may be behind the Mandela Effect? Scientists point to suggestibility as a human characteristic that may provide the clue. After all, many folks on the Internet are quite easily led by memes and less-than-believable tales. But the personal experiences of many point to even more extravagant possibilities. What if some people have different memories because they lived in a different time, or a dimension that is in many ways similar to ours but diverges at certain key moments? 

If people did live in different times or dimensions, the sensation of déjà vu would acquire another potential explanation. When that feeling comes, could it be a memory or a “crossover” from that parallel universe? Maybe a version of you is experiencing the same thing in another dimension and you just become aware of that duality during déjà vu? 

While this may sound outlandish, and fodder for countless discussions on Reddit, Michio Kaku, the noted theoretical physicist and co-founder of string theory, added some fuel to this fire by stating in an interview with Big Think that the parallel universe explanation is not without some merit. He acknowledged that for most cases of déjà vu, the explanation can just be that we entered a space that looks like someplace which “simply elicits fragments of memories that we have stored in our brain.”

But in other situations, Kaku, who believes in multiverses, thinks we may be tuning in and out of parallel dimensions. He uses an analogy from the Nobel Prize-winning physicist Steve Weinberg, who explained how multiverses work by comparing them to radio stations:

Think of radio,” said Kaku. “If you’re inside your living room listening to BBC radio, that radio is tuned to one frequency. But in your living room there are all frequencies—radio Cuba, radio Moscow, the Top 40 rock stations. All these radio frequencies are vibrating inside your living room, but your radio is only tuned to one frequency.”

Check out the whole talk by Kaku here:

Humans are “vibrating waves,” says Kaku. And sometimes we can vibrate in “unison with these other universes,” and other times we can’t. This theory may explain why our unusual experiences categorized under the Mandela Effect and déjà vu tend to come and go.

Another more prosaic connection between the Mandela effect and déjà vu could be that, of course, they may both be just cognitive anomalies—memory quirks or false memories that we shouldn’t pay much attention to. But for the millions of people who experience these “quirks,” a satisfying explanation is still out there. 

--

U.S. Navy controls inventions that claim to change "fabric of reality"

Inventions with revolutionary potential made by a mysterious aerospace engineer for the U.S. Navy come to light.

U.S. Navy ships

Credit: Getty Images
Surprising Science
  • U.S. Navy holds patents for enigmatic inventions by aerospace engineer Dr. Salvatore Pais.
  • Pais came up with technology that can "engineer" reality, devising an ultrafast craft, a fusion reactor, and more.
  • While mostly theoretical at this point, the inventions could transform energy, space, and military sectors.
Keep reading Show less

Why so gassy? Mysterious methane detected on Saturn’s moon

Scientists do not know what is causing the overabundance of the gas.

An impression of NASA's Cassini spacecraft flying through a water plume on the surface of Saturn's moon Enceladus.

Credit: NASA
Surprising Science
  • A new study looked to understand the source of methane on Saturn's moon Enceladus.
  • The scientists used computer models with data from the Cassini spacecraft.
  • The explanation could lie in alien organisms or non-biological processes.
Keep reading Show less

CRISPR therapy cures first genetic disorder inside the body

It marks a breakthrough in using gene editing to treat diseases.

Credit: National Cancer Institute via Unsplash
Technology & Innovation

This article was originally published by our sister site, Freethink.

For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

We can overcome one of the biggest challenges with applying CRISPR clinically.

—JENNIFER DOUDNA

"This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

This is a wonderful day for the future of gene-editing as a medicine.

—FYODOR URNOV

If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

"This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

Quantcast